Bristol Myers Squibb
Q1 2022 Earnings Call
Apr 29, 2022, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and welcome to the Bristol-Myers Squibb 2022 first quarter results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Tim Power, vice president, investor relations.
Please go ahead, sir.
Tim Power -- Vice President, Investor Relations
Thank you, Sergei, and good morning, everyone. Thanks for joining us this morning for our first quarter 2022 earnings call. Joining me this morning with prepared remarks are Giovanni Caforio, our board chair and chief executive officer; and David Elkins, our chief financial officer. Also participating in today's call are Chris Boerner, our chief commercialization officer; and Samit Hirawat, our chief medical officer and head of global drug development.
As you'll note, we've posted slides to bms.com that you can follow along with for Giovanni and David's remarks. But before we get started, I'll read our forward-looking statements. During this call, we'll make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings.
These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change. We'll also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measures are available on bms.com.
And so I'll hand over now to Giovanni.
Giovanni Caforio -- Board Chair and Chief Executive Officer
Thank you, Tim, and good morning, everyone. Let's start with our first quarter performance on Slide 4. This is an important year for Bristol-Myers Squibb, and I'm pleased to share that we've had a strong start to 2022. In fact, just yesterday, the FDA-approved mavacamten or Camzyos.
This is a first-in-class medicine for patients living with symptomatic obstructive HCM. It's an important milestone for patients who up until now had no options to treat the underlying cause of this disease. I'm proud that we're giving hope to patients and improving their quality of life. It's also an important milestone for BMS.